Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0T6WN
|
|||
| Former ID |
DNC001213
|
|||
| Drug Name |
Rilpivirine
|
|||
| Synonyms |
500287-72-9; TMC278; Edurant; TMC 278; UNII-FI96A8X663; R278474; TMC-278; 4-{[4-({4-[(E)-2-Cyanoethenyl]-2,6-Dimethylphenyl}amino)pyrimidin-2-Yl]amino}benzonitrile; CHEBI:68606; FI96A8X663; R 278474; 4-{[4-({4-[(E)-2-cyanovinyl]-2,6-dimethylphenyl}amino)pyrimidin-2-yl]amino}benzonitrile; (E)-4-((4-((4-(2-cyanovinyl)-2,6-dimethylphenyl)amino)pyrimidin-2-yl)amino)benzonitrile; (E)-4-(4-(4-(2-cyanovinyl)-2,6-dimethylphenylamino)pyrimidin-2-ylamino)benzonitrile; W-202888; RPV; Mu O-conotoxin
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Human immunodeficiency virus infection [ICD-11: 1C62; ICD-9: 279.3] | Approved | [1] | |
| Pain [ICD-11: MG30-MG3Z] | Investigative | [2] | ||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H18N6
|
|||
| Canonical SMILES |
CC1=CC(=CC(=C1NC2=NC(=NC=C2)NC3=CC=C(C=C3)C#N)C)C=CC#N
|
|||
| InChI |
1S/C22H18N6/c1-15-12-18(4-3-10-23)13-16(2)21(15)27-20-9-11-25-22(28-20)26-19-7-5-17(14-24)6-8-19/h3-9,11-13H,1-2H3,(H2,25,26,27,28)/b4-3+
|
|||
| InChIKey |
YIBOMRUWOWDFLG-ONEGZZNKSA-N
|
|||
| CAS Number |
CAS 500287-72-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
3718286, 11972346, 14926256, 43042131, 47211694, 47211697, 47211721, 51661424, 57370287, 68530819, 92765310, 92765312, 99445063, 103439143, 104226189, 114526520, 118855328, 124490460, 126650351, 126671558, 131316308, 131465251, 134340246, 134340430, 135246698, 136946573, 137035212, 137185600, 139360872, 144115326, 152041099, 152258256, 160645811, 160647092, 160778753, 160778853, 160778857, 160778861, 160778873, 160778877, 160778884, 160969625, 162011442, 162197408, 162211538, 163884612, 164764879, 164834289, 172121854, 175268205
|
|||
| ChEBI ID |
CHEBI:68606
|
|||
| ADReCS Drug ID | BADD_D01940 ; BADD_D01941 | |||
| SuperDrug ATC ID |
J05AG05
|
|||
| Drug Resistance Mutation (DRM) | Top | |||
|---|---|---|---|---|
| DRM | DRM Info | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Human immunodeficiency virus Reverse transcriptase (HIV RT) | Target Info | Inhibitor | [3] |
| Voltage-gated sodium channel alpha Nav1.8 (SCN10A) | Target Info | Inhibitor | [2] | |
| Reactome | Interaction between L1 and Ankyrins | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. | |||
| REF 2 | Structures of muO-conotoxins from Conus marmoreus. I nhibitors of tetrodotoxin (TTX)-sensitive and TTX-resistant sodium channels in mammalian senso... J Biol Chem. 2004 Jun 11;279(24):25774-82. | |||
| REF 3 | Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.